The U.S. Food and Drug Administration (FDA) granted a supplemental efficacy approval for Synjardy (empagliflozin and metformin hydrochloride) on March 7, 2025. This approval, identified as NDA 206111 S-45, pertains to the drug's demonstrated effectiveness and was issued to the sponsor, Boehringer Ingelheim.
Background
Synjardy is a combination medication that includes empagliflozin and metformin hydrochloride. This supplemental approval specifically addresses the efficacy of the drug, as classified by the FDA. Empagliflozin is also available as a standalone drug (Jardiance) and in other fixed-dose combinations such as Glyxambi (with linagliptin) and Trijardy XR (with linagliptin and metformin hydrochloride). Other drugs related to empagliflozin, often considered in similar therapeutic contexts, include canagliflozin and dapagliflozin.
What this means
This supplemental efficacy approval for Synjardy indicates that the FDA has evaluated and accepted additional data supporting the drug's effectiveness. While the specific details of the expanded indication or population are not provided in the current source, such approvals typically lead to updates in the drug's prescribing information. This development is important for clinicians, researchers, and patient advocates as it may broaden the therapeutic scope of Synjardy, potentially offering new treatment options or refining existing usage guidelines. The approval reflects ongoing efforts by Boehringer Ingelheim to further establish the efficacy profile of their drug products.
Source
The information regarding this supplemental efficacy approval for Synjardy was sourced from the U.S. Food and Drug Administration (FDA). The approval for NDA 206111 S-45 was officially recorded on March 7, 2025, and is accessible via accessdata.fda.gov.